Details of the Drug Combination

General Information of Drug Combination (ID: DC3CY1A)

Drug Combination Name

Tenofovir disoproxil Alendronate

Indication

Disease Entry	Status	REF
Bone Demineralization	Phase 4	[1]

Component Drugs

Tenofovir disoproxil DM62IPN

Alendronate DMY2KX9

N.A.

Small molecular drug

2D MOL

3D MOL is unavailable

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Tenofovir disoproxil Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[4]
------------------------------------------------------------------------------------

Tenofovir disoproxil Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[5]
------------------------------------------------------------------------------------

Indication(s) of Alendronate

Disease Entry	ICD 11	Status	REF
Bone Paget disease	N.A.	Approved	[2]
Exostosis	N.A.	Approved	[2]
Osteoporosis	FB83.0	Approved	[3]
Paget's disease	FB85	Approved	[3]
Prostate adenocarcinoma	N.A.	Approved	[2]

Alendronate Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Geranyltranstransferase (FDPS)	TTIKWV4	FPPS_HUMAN	Modulator	[7]
------------------------------------------------------------------------------------

Alendronate Interacts with 6 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Collagen alpha-1(II) chain (COL2A1)	OT5E59C8	CO2A1_HUMAN	Decreases Expression	[8]
Collagen alpha-1(III) chain (COL3A1)	OTT1EMLM	CO3A1_HUMAN	Decreases Expression	[8]
Osteocalcin (BGLAP)	OTK1YLWQ	OSTCN_HUMAN	Decreases Expression	[8]
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Decreases Expression	[9]
Collagen alpha-3(V) chain (COL5A3)	OTCGC4DM	CO5A3_HUMAN	Decreases Expression	[8]
Ras-related protein Rap-1A (RAP1A)	OT5RH6TI	RAP1A_HUMAN	Decreases Prenylation	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DOT(s)

References

1	ClinicalTrials.gov (NCT02322099) Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss
2	Alendronate FDA Label
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3141).
4	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
5	FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
6	Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes. Clin Endocrinol (Oxf). 2003 Mar;58(3):365-71. doi: 10.1046/j.1365-2265.2003.01724.x.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment. Clin Oral Investig. 2010 Feb;14(1):51-8. doi: 10.1007/s00784-009-0312-2. Epub 2009 Jul 14.
9	Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer. 2004 May;42(5):410-5. doi: 10.1002/pbc.20019.
10	Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone. 2001 Oct;29(4):336-43. doi: 10.1016/s8756-3282(01)00589-0.